ViCardia Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
ViCardia is a clinical stage biopharma company entering Phase 2 with GP531, a potent, infusion therapy for treating mitochondrial dysfunction that is the underlying cause of chronic heart failure that progresses to acute heart failure & hospitalization.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}